Outcome of the Board meeting held on 25th May, 2026
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aarti Pharmalabs Board approved audited FY26 results (standalone and consolidated) ending March 31, 2026. Standalone revenue grew marginally by 1.5% to Rs. 179,755 lakhs from Rs. 177,135 lakhs. However, net profit declined sharply by 31.5% to Rs. 17,620 lakhs from Rs. 25,735 lakhs in FY25, impacted by higher finance costs (Rs. 4,690 vs Rs. 2,563 lakhs), increased depreciation, and foreign exchange losses. The Board declared a final dividend of Rs. 2 per share (40% on Rs. 5 face value). An exceptional item of Rs. 279.49 lakhs was recorded for new labour code provisions. The company restated Q3 FY26 figures due to a previously omitted forward contract fair value adjustment of Rs. 2,972.94 lakhs. Auditors issued unmodified (clean) opinions. Two senior management personnel were designated.
The sharp 31.5% decline in net profit despite flat revenue growth signals margin compression and higher financial costs, which may concern shareholders. However, the clean audit opinion and dividend declaration provide some comfort.